bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Signatures and mechanisms of efficacious therapeutic ribonucleotides against SARSCoV-2 revealed by analysis of its replicase using magnetic tweezers
Mona Seifert1, â€ , Subhas Chandra Bera1, â€ , Pauline van Nies1, Robert N. Kirchdoerfer2,
Ashleigh Shannon3, Thi-Tuyet-Nhung Le3, Tyler L. Grove4, FlÃ¡via S. Papini1, Jamie J. Arnold5,
Steven C. Almo4, Bruno Canard3, Martin Depken6, Craig E. Cameron5, and David Dulin1,*

1

Junior Research Group 2, Interdisciplinary Center for Clinical Research, FriedrichAlexander-University Erlangen-NÃ¼rnberg (FAU), Cauerstr. 3, 91058 Erlangen,
Germany

2

Department of Biochemistry and Institute of Molecular Virology, University of
Wisconsin-Madison, Madison, WI 53706

3

Architecture et Fonction des MacromolÃ©cules Biologiques, CNRS and Aix-Marseille
UniversitÃ©, UMR 7257, Polytech Case 925, 13009 Marseille, France.

4

Department of Biochemistry, Albert Einstein College of Medicine, Bronx, NY, USA
Institute for Protein Innovation, Boston, MA, USA

5

Department of Microbiology and Immunology, University of North Carolina School of
Medicine, Chapel Hill, NC 27514 USA

6

Department of Bionanoscience, Kavli Institute of Nanoscience, Delft University of
Technology, Van der Maasweg 9, 2629 HZ Delft, The Netherlands

â€  These authors contributed equally to this work.
âˆ—Corresponding author: Email: david.dulin@uk-erlangen.de

1

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Summary
Coronavirus Disease 2019 (COVID-19) results from an infection by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), the third coronavirus outbreak to plague humanity
this century. Currently, the most efficacious therapeutic against SARS-CoV-2 infection is the
Remdesivir (RDV), an adenine-like ribonucleotide analogue that is very efficiently
incorporated by the SARS-CoV-2 replicase. Understanding why RDV is so well incorporated
will facilitate development of even more effective therapeutics. Here, we have applied a highthroughput, single-molecule, magnetic-tweezers platform to study thousands of cycles of
nucleotide addition by the SARS-CoV-2 replicase in the absence and presence of RDV, a
Favipiravir-related analog (T-1106), and the endogenously produced ddhCTP. Our data are
consistent with two parallel catalytic pathways of the replicase: a high-fidelity catalytic (HFC)
state and a low-fidelity catalytic (LFC) state, the latter allowing the slow incorporation of both
cognate and non-cognate nucleotides. ddhCTP accesses HFC, T-1106 accesses LFC as a noncognate nucleotide, while RDV efficiently accesses both LFC pathway. In contrast to previous
reports, we provide unequivocal evidence against RDV functioning as a chain terminator. We
show that RDV incorporation transiently stalls the replicase, only appearing as termination
events when traditional, gel-based assays are used. The efficiency of ddhCTP utilization by the
SARS-CoV-2 replicase suggests suppression of its synthesis during infection, inspiring new
therapeutic strategies. Use of this experimental paradigm will be essential to the development
of therapeutic nucleotide analogs targeting polymerases.

Introduction
SARS-CoV-2 has infected almost twenty million humans worldwide, causing approximately
700,000 deaths as August 5th, with numbers still on the rise. We are currently living through
the third coronavirus outbreak in less than twenty years, and we are desperately in need of
broad-spectrum antiviral drugs that are capable of targeting this emerging family of human
pathogens. To this end, nucleotide analogues (NAs) represent a powerful approach, as they
target the functionally and structurally conserved coronavirus replicase, and their insertion in
the viral RNA induces either premature termination or a lethal increase in mutations. The
coronavirus replicase is composed of the RNA-dependent RNA polymerase (RdRp) nsp12, and
the nsp7 and nsp8 co-factors, with a stoichiometry of 1:1:2

1-4

. This core replicase associates

with several additional viral proteins, including the 5â€™-to-3â€™ helicase nsp13 5 and the 3â€™-to-5â€™
exonuclease nsp14

6-11

. The latter proofreads the RNA synthesized by the high error prone

RdRp nsp12 12, a unique feature of coronavirus in the RNA virus world, and therefore plays a
2

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

central role in contributing to the stability of the unusually large coronavirus genome, i.e. ~30
kb. Furthermore, nsp14 confers coronavirus resistance against many established NAs (e.g.,
ribavirin 13) and therefore presents a challenge for the development of potent NAs. Remdesivir
(RDV) is a recently discovered NA that showed efficacy against Ebola infection
been successfully repurposed for the treatment of coronavirus infection

6,15-19

14

, and has

. The success of

RDV relies on its efficient incorporation by nsp12 16, and probable evasion from excision by
nsp14 6. Understanding how RDV achieves these two tasks will help to guide the rational design
of more efficacious NAs for the current and future outbreaks. To this end, it is essential to build
a comprehensive model describing the selection and incorporation mechanisms that control the
utilization of NAs by coronavirus replicase and to define the determinants of the base and ribose
responsible for selectivity and potency. The generation of such model is however hampered by
the inability of standard biochemical techniques to work in physiological conditions involving
saturating concentrations of competing NTP and kilobase-long template, while maintaining
single base resolution.

Results
Monitoring SARS-CoV-2 replication at the single molecule level
To enable the observation of rare events, such as nucleotide mismatch and NA incorporation,
even in the presence of saturating NTP concentration, we have developed a single molecule,
high throughput, magnetic tweezers assay to monitor SARS-CoV-2 replication activity at near
single base resolution 20. A SARS-CoV-2 replicase formed of nsp12, nsp7 and nsp8 assembles
and initiates replication at the 3â€™ end of the magnetic bead-attached handle, and converts the
1043 nt long single stranded RNA template into a double-stranded (ds) RNA in the presence of
NTPs (Fig. 1a, Extended data Fig. 1ab, Materials and Methods). The magnetic bead
displacement along the vertical axis directly informs on the number of incorporated nucleotides
(Fig. 1a, Materials and Methods) 21. During each experiment, hundreds of magnetic beads are
followed in parallel (Extended data Fig. 1c), providing dozens of SARS-CoV-2 replication
activity traces per experiment (Fig. 1b). As previously observed for other viral RdRps 20-22, the
traces present a lot of dynamics, with bursts of activity interrupted by pauses of duration varying
from ~0.5 s to ~60 s in Fig. 1b. To extract the elongation kinetics of SARS-CoV-2 replicase,
we scanned the traces with non-overlapping windows of 10 nt to measure the ten successive
nucleotide incorporations total duration, which we coined dwell time

20-22

(Materials and

Methods). We fitted the distribution of dwell times using the stochastic-pausing model that
describes well the fidelity and kinetics of nucleotide addition of viral RdRps

20-23

(Fig. 1c,
3

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Materials and Methods), and in particular for poliovirus RdRp, a prototypical enterovirus
RdRp to which SARS-CoV-1 nsp12 ressembles the most 1. This model is composed of four
distributions, describing the pause-free nucleotide addition rate, Pause 1, Pause 2 and the longlived pauses (Fig. 1c). Statistics and all parameter values extracted from the analysis are
reported in Extended data Table 1. Viral RdRps, such as the one of poliovirus, are robustly
described by a kinetic model where the nucleotide addition rate is the kinetic signature of a fast
and high fidelity catalytic (HFC) state, from which the RdRp stochastically and rarely switches
into a lower fidelity catalytic (LFC) state that runs parallel to the HFC state (Fig. 1d) 20-22. Pause
1 and Pause 2 are the kinetic signatures of the LFC state, and relate to the slow incorporation
of a cognate base following either a cognate, i.e. diagonal arrow in Fig. 1d, or a mismatch base
incorporation, i.e. terminal mismatch catalytic state (TMC) in Fig. 1d, respectively. On the
other hand, the long-lived pauses relate to a catalytically incompetent state 21. Increasing the
temperature from 25Â°C to 37Â°C, SARS-CoV-2 replicase reveals a strong temperature
dependence, which translates into a 2-fold decrease in median of the total replication time, from
(25 Â± 1) ğ‘ ğ‘  to (12.0 Â± 0.4) ğ‘ ğ‘  (median Â± standard deviation (Fig. 1e)), while not affecting the
replication product length (Fig. 1f). Analyzing the dwell time distribution at 25 and 37Â°C (Fig.

1g), we extracted a ~2.6-fold enhancement in nucleotide addition rate, i.e. from
(65.6 Â± 0.5) ğ‘ ğ‘  âˆ’1 to (169 Â± 4) ğ‘ ğ‘  âˆ’1, making nsp12 the fastest RNA polymerase characterized
to date (Fig. 1h). Pause 1 and Pause 2 exit rates also increased by ~2-fold (Fig. 1h), whereas

their respective probabilities increased by 2- and 5-fold (Extended data Fig. 1d). The latter
results are rather surprising, as enterovirus RdRps showed only an exit rate increase with no
change in probability 22.

3â€™-dATP versus Remdesivir-TP: two ATP competitors, two modes of incorporation
Next, we investigated how the elongation kinetics and the product length of SARS-CoV-2
replicase were affected by two adenosine analogues, i.e. 3â€™-dATP and RDV-TP (Extended
data Fig. 2). 3â€™-dATP is an obligatory terminator and a recent study showed that
dideoxynucleotides were incorporated by SARS-CoV-1 replicase 8. In the presence of 500 ÂµM
NTP and 500 ÂµM 3â€™-dATP, SARS-CoV-2 replication demonstrated an increase in the number
of traces that did not reach the end of the template (1043 nt) (Fig. 2a versus Fig. 1b). Indeed,
increasing 3â€™-dATP concentration up to 2000 ÂµM, i.e. a stoichiometry equal to four, reduced
the mean product length of SARS-CoV-2 replicase by ~1.7-fold, i.e. from (940 Â± 13) ğ‘›ğ‘›ğ‘›ğ‘› to
(566 Â± 33 ) ğ‘›ğ‘›ğ‘›ğ‘› (mean Â± standard deviation) (Fig. 2b), while neither affected the replication
time nor the elongation kinetics (Fig. 2c, Extended data Fig. 3abc). We derived a model to

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

determine the effective incorporation rate ğ›¾ğ›¾ of a NA chain terminator against an equimolar

concentration of the competing nucleotide, i.e. a stoichiometry of 1 (Materials and Methods).
This model fits very well the mean product length as a function of 3â€™-dATP stoichiometry
against ATP (Fig. 2b), i.e. ğ›¾ğ›¾3â€² âˆ’ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘,500 Âµğ‘€ğ‘€ ğ´ğ´ğ´ğ´ğ´ğ´ = (780 Â± 64) ğ‘›ğ‘›ğ‘›ğ‘›, meaning that the replicase
incorporates on average 780 nt before incorporating one 3â€™-dATP and terminating replication

(Materials and Methods). A subsaturating concentration of NTP increases the probability to
enter the LFC state (Fig. 1d) 20,21, i.e. Pause 1 and Pause 2 probability, and would increase the
effective incorporation rate of 3â€™-dATP, providing it is incorporated via the LFC state.
Decreasing ATP concentration from 500 to 50 ÂµM, we observed an increase in Pause 1 and
Pause 2 probabilities by more than 2-fold and 3-fold, i.e. from (0.060 Â± 0.002) to
(0.149 Â± 0.005)

and

from

(0.0033 Â± 0.0009) to

(0.0115 Â± 0.0026),

respectively

(Extended data Fig. 3a-f), respectively, and the replication traces appeared shorter than at 500
ÂµM ATP (Fig. 2d). However, the effective incorporation rate of 3â€™-dATP was identical at both
concentrations of ATP, i.e. ğ›¾ğ›¾3â€² âˆ’ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘,50 Âµğ‘€ğ‘€ ğ´ğ´ğ´ğ´ğ´ğ´ = (777 Â± 50) ğ‘›ğ‘›ğ‘›ğ‘› (Fig. 2e), which indicates that

3â€™-dATP incorporation is only driven by stoichiometry, despite the significant increase in the
LFC state probabilities (Pause 1 and Pause 2). Therefore, we conclude that 3â€™-dATP is
incorporated through the HFC state (Fig. 1d). This interpretation is further supported by steady
state kinetics analysis of 3â€™-dATP incorporation by poliovirus RdRp, which showed that 3â€™dATP is much more promiscuous than any mismatch on a uracil 24. Of note, the decrease in the
median replication time is due to the shortening of the product length from early termination
(Extended data Fig. 3g). Despite its good incorporation rate, 3â€™-dATP is not a good candidate
to treat coronavirus infection, because of its toxicity 25. Therefore, a less toxic and promiscuous
NA is required to compete against ATP. RDV-TP is an adenine analogue with a 1â€™-cyano
modification that has recently been shown to outcompete ATP for incorporation

16

, while

having a low cytotoxicity 26. RDV-TP has been proposed to induce delayed chain termination
at i+3 (i being RDV incorporation position) during coronavirus replication

15,16

. Adding 100

ÂµM RDV-TP in a reaction buffer containing 500 ÂµM NTPs showed a dramatic increase in the
pause density and duration, while most of the traces reached the end of the template (Fig. 2f).
We indeed observed a final product length largely unaffected at all concentrations of RDV-TP
(Fig. 2g), while the median replication time increased by more than 10-fold, i.e. from
(25 Â± 1) ğ‘ ğ‘  to (315 Â± 14) ğ‘ ğ‘  (Fig. 2h) for RDV-TP concentration increasing up to 300 ÂµM.
Therefore, the RDV-TP mechanism of action is not termination. We then investigated the origin

of the pause induced by RDV-TP incorporation using our pause-stochastic model (Fig. 2i,
Extended data Fig. 4a). While the nucleotide addition rate is unaffected by RDV-TP, all
5

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

pauses are significantly impacted. The exit rates of Pause 1 and Pause 2 decreased by 4- and
10-fold (Fig. 2j), while their probabilities increased by 2- and 4-fold, respectively (Fig. 2k).
Most notably, the long-lived pause probability increased by 28-fold, i.e. from (0.0005 Â±

0.0001) to (0.0142 Â± 0.0015) when increasing RDV-TP concentration up to 300 ÂµM. The

long-lived pause probability increase was such that it most likely affected the probability and
the exit rates of Pause 1 and Pause 2 above 50 ÂµM RDV-TP (Fig. 2k). To better disentangle
the pause distributions, we performed a SARS-CoV-2 replication experiments at 37Â°C with 100

ÂµM RDV-TP (Extended data Fig. 4b). We observed the same nucleotide addition rate with
and without RDV-TP (Fig. 1bef), while Pause 1 and Pause 2 exit rates significantly decreased
by 3- and 9-fold, respectively (Extended data Fig. 4c). On the other hand, Pause 1 and Pause
2 probabilities were unaffected by the presence of RDV-TP (Extended data Fig. 4d),
supporting the notion that the increase in probability in the experiments performed at 25Â°C was
the consequence of the long-lived pauses biasing Pause 1 and Pause 2 distributions 20. The longlived pause probability increased by more than 7-fold, i.e. from (0.0003 Â± 0.0001) to
(0.0022 Â± 0.0007). As RDV-TP incorporation pauses SARS-CoV-2 replicase, incorporation

via the HFC state would increase a probability of Pause 1 and Pause 2. Here, we observed
constant probabilities for Pause 1 and Pause 2, while their respective exit rates decreased,
suggesting that RDV-TP is incorporated through the LFC state, behaving like a cognate
(diagonal arrow in Fig. 1d) and as a non-cognate base (TMC, Fig. 1d), i.e. not opposite uracil.
As expected, the almost identical SARS-CoV-1 replicase1 demonstrated a similar kinetic
signature to RDV-TP incorporation (Extended data Fig. 5a-f, Table 1), though to a lesser
extent, e.g. the long-lived pause probability increased by ~9-fold when raising RDV-TP
concentration up to 300 ÂµM versus 28-fold for SARS-CoV-2 replicase.

T-1106-TP is incorporated via the LFC state and with a low probability
Pyrazine-carboxamide is a promising family of antiviral NA, from which the best-known
member is Favipiravir (T-705), recently approved to treat influenza virus infection

27

, and

considered against SARS-CoV-2. We studied here another member of this family, T-1106
triphosphate (T-1106-TP), which is chemically more stable than T-705, while presenting
similar antiviral properties 12,20. T-1106-TP competes for incorporation against ATP and GTP
in a sequence-dependent context

12,20

. Adding 500 ÂµM of T-1106-TP in a reaction buffer

containing 500 ÂµM NTPs significantly increased the number and duration of pauses observed
in SARS-CoV-2 replication traces (Fig. 3a), leading to a 2.6-fold increase in median replication
time, i.e. from (25 Â± 1) ğ‘ ğ‘  to (65 Â± 4) ğ‘ ğ‘  (Fig. 3b). For comparison, 50 ÂµM of RDV-TP induced
6

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

a median replication time of (72 Â± 6) ğ‘ ğ‘  at the same concentration of competing NTP,
suggesting that RDV-TP is better incorporated than T-1106-TP. The final product length was

not affected by T-1106-TP, supporting that T-1106-TP mechanism of action is not termination
(Fig. 3c). Investigating how increasing T-1106-TP concentration affects SARS-CoV-2
replication kinetics (Fig. 3d, Extended data Fig. 6), we found that only Pause 2 exit rate was
affected, decreasing by 10-fold, i.e. from (1.59 Â± 0.21) ğ‘ ğ‘  âˆ’1 to (0.16 Â± 0.01) ğ‘ ğ‘  âˆ’1 (Fig. 3e). On
the other hand, Pause 1 and Pause 2 probabilities remained constant (Extended data Fig. 3f).

Our results suggest an incorporation of T-1106-TP via the LFC state, but only on the mismatch
pathway, i.e. the TMC state (Extended data Fig. 1d), which explains its lesser promiscuity
than RDV-TP. Interestingly, the probability to enter the long-lived pause state increased by
almost 5-fold, i.e. from (0.0005 Â± 0.0001) to (0.0023 Â± 0.0004) (Fig. 3f). For poliovirus
RdRp, we observed that T-1106-TP incorporation induced pauses with context dependent

durations 20, and we suggest that the incorporation of T-1106-TP in a different sequence context
may result in pauses of different natures, i.e. Pause 2 and long-lived pause.

ddhCTP represents a promising NA against coronavirus infection
Finally, we have compared two chain terminators, i.e. Sofosbuvir and ddhCTP. Sofosbuvir is a
uridine analog and FDA approved drug to treat hepatitis C virus infection
incorporated by SARS-CoV-2 replicase

16,19

28,29

and is

. 3Ê¹-deoxy-3â€²,4Ê¹-didehydro-CTP (ddhCTP) is a

recently discovered natural antiviral NA produced in mammalian cells by the viperin-catalyzed
conversion of CTP via a radical-based mechanism

30

. While ddhCTP has been shown to

efficiently terminate flavivirus replication both in vitro and in vivo, its antiviral activity against
SARS-CoV-2 replicase remains unknown. The presence of 500 ÂµM Sofosbuvir-TP with 500
ÂµM NTP did not affect the replication of SARS-CoV-2 (Fig. 4a), while early termination events
appeared in the presence of 500 ÂµM ddhCTP (Fig. 4b). Supporting this visual observation,
SARS-CoV-2 mean replication product length was unaffected by the presence of SofosbuvirTP (Fig. 4c), while raising the ddhCTP (Fig. 4d) stoichiometry against CTP up to 4 reduced
the mean product length from (940 Â± 13) ğ‘›ğ‘›ğ‘›ğ‘› to (622 Â± 24) ğ‘›ğ‘›ğ‘›ğ‘›, showing an effective

incorporation rate ğ›¾ğ›¾ğ‘‘ğ‘‘ğ‘‘ğ‘‘â„ğ¶ğ¶ğ¶ğ¶ğ¶ğ¶,500 Âµğ‘€ğ‘€ ğ¶ğ¶ğ¶ğ¶ğ¶ğ¶ = (1221 Â± 130) ğ‘›ğ‘›ğ‘›ğ‘› (Fig. 4d). For both NAs, the

replication time was unaffected (Extended data Fig. 7a and 8a), as well as SARS-CoV-2

replication kinetics (Extended data Fig. 7b-d and 7f-h). Reducing the concentration of their
respective competing NTP down to 50 ÂµM and keeping the other NTPs at 500 ÂµM, SofosbuvirTP showed few early termination events when added at 500 ÂµM (Fig. 4e), while only a small
number of traces reached the end of the template at the same concentration of ddhCTP (Fig.
7

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

4f). The analysis showed a limited impact of Sofosbuvir-TP on the mean product length, i.e.
with a minimum of (563 Â± 32) ğ‘›ğ‘›ğ‘›ğ‘› at a stoichiometry of 20 (Fig. 4g), while ddhCTP was more
effectively incorporated, shortening the mean product length down to (284 Â± 23) ğ‘›ğ‘›ğ‘›ğ‘› at the
same stoichiometry (Fig. 4h). Their respective effective incorporation rate at stoichiometry of
1

reflected

these

observations,

i.e.

ğ›¾ğ›¾ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ğ‘ ,50 Âµğ‘€ğ‘€ ğ‘ˆğ‘ˆğ‘ˆğ‘ˆğ‘ˆğ‘ˆ = (3908 Â± 467) ğ‘›ğ‘›ğ‘›ğ‘›

and

ğ›¾ğ›¾ğ‘‘ğ‘‘ğ‘‘ğ‘‘â„ğ¶ğ¶ğ¶ğ¶ğ¶ğ¶,50 Âµğ‘€ğ‘€ ğ¶ğ¶ğ¶ğ¶ğ¶ğ¶ = (1360 Â± 71) ğ‘›ğ‘›ğ‘›ğ‘›. In other words, SARS-CoV-2 replicase incorporates in

average 3908 and 1360 nt before incorporating a single Sofosbuvir-TP and ddhCTP,
respectively, and terminate replication. Replication kinetics were unaffected by the presence of
ddhCTP or Sofosbuvir-TP, while their median replication time mildly decreased at high
stoichiometry, highlighting the shortening of the replication product (Extended data Fig. 7ah and 8a-h, respectively). As for 3â€™-dATP, our data suggest that stoichiometry against the
competing NTP regulates Sofosbuvir-TP and ddhCTP incorporation, which are therefore
incorporated via the HFC state (Fig. 1d). On the one hand, our data confirmed the poor
incorporation of Sofosbuvir by SARS-CoV-2

16,31

. On the other hand, ddhCTP showed an

interesting increase in termination activity at physiological CTP concentration, opening great
perspectives for ddhCTP as an effective anti-coronavirus NA with a low cytotoxicity.

Discussion
We present here the first observation of SARS-CoV-2 replication activity at the single molecule
level. We show that SARS-CoV-2 replicase is the fastest RNA polymerase to date, replicating
up to ~170 nt/s at 37Â°C. With our assay we characterized the incorporation rate and mechanism
of action of several NAs, i.e. 3â€™-dATP, Sofosbuvir-TP, ddhCTP, T-1106-TP and RDV-TP.
Here, we showed that RDV-TP is incorporated by both pathways of the LFC state, i.e. as a
cognate base (diagonal arrow in Fig. 1d) and as a mismatch (TMC state in Fig. 1d). In contrast,
T-1106-TP is only incorporated via the TMC state. At a saturating concentration of NTP, Pause
1 (kinetic signature of cognate base incorporation by LFC) and Pause 2 (kinetic signature of
mismatch incorporation by LFC) respectively account for ~6% and ~0.3% of all the nucleotide
addition events, which therefore defines an upper limit for RDV-TP and T-1106-TP relative
incorporation, and explains why RDV-TP is much better incorporated than Favipiravir31. A
recent study performed at submicromolar NTPs showed that RDV-TP is three times better
incorporated than ATP 16. At such low NTP concentration, the LFC state is predominant over
the HFC state 20,21, which would suggest that the measured selectivity is only valid for the LFC
state. Nonetheless, RDV-TP may still be incorporated via the HFC state, generating a longlived pause, which would explain the observed surge in probability for this type of pause.
8

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

However, other explanations for this surge are also likely, e.g. multiple RDV-TP incorporation
in a single dwell time, sequence-dependent context pause associated with RDV-TP
incorporation

20

. Importantly, we unambiguously showed that both RDV-TP and T-1106-TP

are not terminators, but rather slow down replication. Concerning obligatory terminators, the
effective incorporation rate we measured showed that 3â€™-dATP and ddhCTP are well
incorporated by SARS-CoV-2 replicase, while Sofosbuvir-TP is strongly outcompeted by UTP.
Interestingly, all of them are incorporated via the HFC state, i.e. behaving like a cognate base
(Fig. 1d), supporting a mechanism where base pairing is the main discriminator by which state,
i.e. HFC or LFC, is the analogue incorporated, and we are able to determine their respective
effective incorporation rate. A recent steady-state kinetic study showed that nucleotide
analogues modified at the 2â€™ and 3â€™ positions are strongly discriminated against their competing
natural nucleotide 16. Such selectivity is an issue for purine-based analogues which competes
with high concentrations of ATP and GTP in the cell, but not for pyrimidine-based analogues,
as derivatives of CTP, which compete with CTP at an intracellular concentration of ~100 ÂµM
32

. These features make ddhCTP a particularly attractive antiviral NA. Furthermore, under

certain conditions, the interferon Î±-induced viperin converts up to 30% the cellular pool of CTP
into ddhCTP, further increasing its stoichiometry and favoring its potency 30. This may explain
why SARS-CoV-2 viral proteins inhibits the interferon response

33

. ddhCTP therefore

represents an exciting viral replication inhibitor with a low cytotoxicity and high efficacy.
Given these insighful results, we anticipate that our assay will become the new standard to
determine the selectivity and the mode of action of NAs. Future work will focus on assembling
a complete coronavirus replicase, e.g. including the helicase nsp13 and the exonuclease nsp14,
to evaluate their impact on SARS-CoV-2 replication, proofreading and NA efficacy.

References and notes:

1

2
3
4
5

Kirchdoerfer, R. N. & Ward, A. B. Structure of the SARS-CoV nsp12 polymerase
bound to nsp7 and nsp8 co-factors. Nature communications 10, 2342,
doi:10.1038/s41467-019-10280-3 (2019).
Hillen, H. S. et al. Structure of replicating SARS-CoV-2 polymerase. Nature,
doi:10.1038/s41586-020-2368-8 (2020).
Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus.
Science (New York, N.Y 368, 779-782, doi:10.1126/science.abb7498 (2020).
Wang, Q. et al. Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase.
Cell 182, 417-428 e413, doi:10.1016/j.cell.2020.05.034 (2020).
Chen, J. et al. Structural basis for helicase-polymerase coupling in the SARS-CoV-2
replication-transcription complex. bioRxiv, doi:10.1101/2020.07.08.194084 (2020).
9

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

6

7

8

9

10

11

12
13

14

15

16

17

18

19

20

Agostini, M. L. et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734)
Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. Mbio 9,
doi:10.1128/mBio.00221-18 (2018).
Bouvet, M. et al. RNA 3'-end mismatch excision by the severe acute respiratory
syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex.
Proceedings of the National Academy of Sciences of the United States of America 109,
9372-9377, doi:10.1073/pnas.1201130109 (2012).
Ferron, F. et al. Structural and molecular basis of mismatch correction and ribavirin
excision from coronavirus RNA. Proceedings of the National Academy of Sciences of
the United States of America 115, E162-E171, doi:10.1073/pnas.1718806115 (2018).
Ogando, N. S. et al. The Curious Case of the Nidovirus Exoribonuclease: Its Role in
RNA Synthesis and Replication Fidelity. Front Microbiol 10, 1813,
doi:10.3389/fmicb.2019.01813 (2019).
Subissi, L. et al. One severe acute respiratory syndrome coronavirus protein complex
integrates processive RNA polymerase and exonuclease activities. Proceedings of the
National Academy of Sciences of the United States of America 111, E3900-3909,
doi:10.1073/pnas.1323705111 (2014).
Eckerle, L. D., Lu, X., Sperry, S. M., Choi, L. & Denison, M. R. High fidelity of murine
hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. Journal of
virology 81, 12135-12144, doi:10.1128/JVI.01296-07 (2007).
Shannon, A. et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA
polymerase. bioRxiv, doi:10.1101/2020.05.15.098731 (2020).
Smith, E. C., Blanc, H., Surdel, M. C., Vignuzzi, M. & Denison, M. R. Coronaviruses
lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for
proofreading and potential therapeutics. PLoS pathogens 9, e1003565,
doi:10.1371/journal.ppat.1003565 (2013).
Siegel, D. et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a
Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of
Ebola
and
Emerging
Viruses.
J
Med
Chem
60,
1648-1661,
doi:10.1021/acs.jmedchem.6b01594 (2017).
Gordon, C. J., Tchesnokov, E. P., Feng, J. Y., Porter, D. P. & Gotte, M. The antiviral
compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle
East respiratory syndrome coronavirus. The Journal of biological chemistry 295, 47734779, doi:10.1074/jbc.AC120.013056 (2020).
Gordon, C. J. et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent
RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high
potency.
The
Journal
of
biological
chemistry
295,
6785-6797,
doi:10.1074/jbc.RA120.013679 (2020).
Pruijssers, A. J. & Denison, M. R. Nucleoside analogues for the treatment of
coronavirus infections. Curr Opin Virol 35, 57-62, doi:10.1016/j.coviro.2019.04.002
(2019).
Jockusch, S. et al. A library of nucleotide analogues terminate RNA synthesis catalyzed
by polymerases of coronaviruses that cause SARS and COVID-19. Antiviral research
180, 104857, doi:10.1016/j.antiviral.2020.104857 (2020).
Chien, M. et al. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key
Drug Target for COVID-19. J Proteome Res, doi:10.1021/acs.jproteome.0c00392
(2020).
Dulin, D. et al. Signatures of Nucleotide Analog Incorporation by an RNA-Dependent
RNA Polymerase Revealed Using High-Throughput Magnetic Tweezers. Cell Rep 21,
1063-1076, doi:10.1016/j.celrep.2017.10.005 (2017).

10

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

21

22

23

24

25

26

27

28

29

30
31

32
33

34
35

36

37
38

Dulin, D. et al. Elongation-Competent Pauses Govern the Fidelity of a Viral RNADependent RNA Polymerase. Cell Rep 10, 983-992, doi:10.1016/j.celrep.2015.01.031
(2015).
Seifert, M. et al. Temperature controlled high-throughput magnetic tweezers show
striking difference in activation energies of replicating viral RNA-dependent RNA
polymerases. Nucleic acids research, doi:10.1093/nar/gkaa233 (2020).
Dulin, D., Berghuis, B. A., Depken, M. & Dekker, N. H. Untangling reaction pathways
through modern approaches to high-throughput single-molecule force-spectroscopy
experiments. Curr Opin Struct Biol 34, 116-122, doi:10.1016/j.sbi.2015.08.007 (2015).
Castro, C., Arnold, J. J. & Cameron, C. E. Incorporation fidelity of the viral RNAdependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus
Res 107, 141-149, doi:10.1016/j.virusres.2004.11.004 (2005).
Arnold, J. J. et al. Sensitivity of mitochondrial transcription and resistance of RNA
polymerase II dependent nuclear transcription to antiviral ribonucleosides. PLoS
pathogens 8, e1003030, doi:10.1371/journal.ppat.1003030 (2012).
Pruijssers, A. J. et al. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and
Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep
32, 107940, doi:10.1016/j.celrep.2020.107940 (2020).
Furuta, Y. et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum
inhibitors of RNA viral infections. Antiviral research 82, 95-102,
doi:10.1016/j.antiviral.2009.02.198 (2009).
Kayali, Z. & Schmidt, W. N. Finally sofosbuvir: an oral anti-HCV drug with wide
performance
capability.
Pharmgenomics
Pers
Med
7,
387-398,
doi:10.2147/PGPM.S52629 (2014).
Sofia, M. J. et al. Discovery of a beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-Cmethyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J
Med Chem 53, 7202-7218, doi:10.1021/jm100863x (2010).
Gizzi, A. S. et al. A naturally occurring antiviral ribonucleotide encoded by the human
genome. Nature 558, 610-614, doi:10.1038/s41586-018-0238-4 (2018).
Xie, X. et al. A nanoluciferase SARS-CoV-2 for rapid neutralization testing and
screening
of
anti-infective
drugs
for
COVID-19.
bioRxiv,
doi:10.1101/2020.06.22.165712 (2020).
Traut, T. W. Physiological concentrations of purines and pyrimidines. Molecular and
cellular biochemistry 140, 1-22, doi:10.1007/BF00928361 (1994).
Sa Ribero, M., Jouvenet, N., Dreux, M. & Nisole, S. Interplay between SARS-CoV-2
and the type I interferon response. PLoS pathogens 16, e1008737,
doi:10.1371/journal.ppat.1008737 (2020).
Ostrofet, E., Papini, F. S. & Dulin, D. Correction-free force calibration for magnetic
tweezers experiments. Sci Rep 8, 15920, doi:10.1038/s41598-018-34360-4 (2018).
Papini, F. S., Seifert, M. & Dulin, D. High-yield fabrication of DNA and RNA
constructs for single molecule force and torque spectroscopy experiments. Nucleic acids
research, doi:10.1093/nar/gkz851 (2019).
Cnossen, J. P., Dulin, D. & Dekker, N. H. An optimized software framework for realtime, high-throughput tracking of spherical beads. The Review of scientific instruments
85, 103712, doi:10.1063/1.4898178 (2014).
Cowan, G. Statistical Data Analysis. (Oxford University Press, 1998).
Press, W. H., Flannery, B. P., Teukolsky, S. A. & Vetterling, W. T. NUMERICAL
RECIPES IN C: THE ART OF SCIENTIFIC COMPUTING. (Cambridge University
Press, 1992).

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Author contribution: DD and CEC conceived the research. MS, SCB and DD performed and
analyzed the single molecule experiments. PvN wrote the MLE analysis routine. MD derived
the terminator competition model. TG and SCA provided ddhCTP. BC, TTNL and AS provided
SARS-CoV-1 proteins. RNK provided SARS-CoV-2 proteins. DD and CEC wrote the article.
All the authors have discussed the data and edited the article.

Acknowledgements: We thank Joy Feng from Gilead Sciences to provide RDV-TP, and
Veronique Fattorini and Barbara Selisko for excellent technical assistance and help in the
experiments. DD was supported by the Interdisciplinary Center for Clinical Research (IZKF)
at the University Hospital of the University of Erlangen-Nuremberg. RNK was supported by
the National Institutes of Health, National Institute for Allergy and Infectious Disease
(AI123498). AS, TTNL and BC acknowledge grants by the Fondation pour la Recherche
MÃ©dicale (Aide aux Ã©quipes), the SCORE project H2020 SC1-PHE-Coronavirus-2020
(grant#101003627), and the REACTing initiative (REsearch and ACTion targeting emerging
infectious diseases).

Competing interests: Authors declare no competing interest

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Fig. 1. SARS-CoV-2 replicase is a fast and processive viral replication complex. a,
Schematic of magnetic tweezers assay to monitor RNA synthesis by the SARS-CoV-2 replicase
complex. A magnetic bead is attached to a glass coverslip surface by a 1043 long ssRNA
construct that experiences a constant force F. The replicase formed by nsp7, nsp8 and nsp12
assembles at the 3â€™-end of the RNA strand annealed to the template. The subsequent conversion
of the ssRNA template into dsRNA reduces the end-to-end extension of the tether, signaling
replication activity. b, SARS-CoV-2 replication traces acquired at either 25Â°C (gray) or 37Â°C
(black), showing bursts of nucleotide addition interrupted by pauses. The inset is a zoom-in of
the traces captured in the red square. c, The dwell times collected from (b) are assembled into
a distribution that is fitted using a pause-stochastic model (Materials and Methods) (solid
lines). The model includes four different probability distribution functions that describe the
event that kinetically dominates the dwell time: uninterrupted ten nucleotide additions (green);
exponentially distributed Pause 1 and 2 (blue and cyan, respectively); and the power law
distributed long-lived pauses (red). d, The dwell time distribution in (c) is described by the viral
RdRp kinetic model (adapted from Ref. 21). Nucleotide addition is achieved via two competing
pathways, i.e. the high fidelity catalytic (HFC) state and the low fidelity catalytic (LFC) state,
which leads to either cognate, i.e. diagonal arrow, or non cognate nucleotide incorporation, i.e.
terminal mismatch catalytic (TMC). The former dominates at high NTP concentration, is fast
and accurate, while the latter dominates at low NTP concentration, is slow and error prone.
Pause 1 and Pause 2 are the kinetic signature of cognate and mismatch nucleotide additions,
respectively, by the LFC state. e, Total replication time and f, replication product length of
SARS-CoV-2 replication activity at either 25Â°C or 37Â°C. The median total replication time and
mean product length are indicated above the violin plots, and represented as thick horizontal
lines. The error bars represent one standard deviation extracted from 1000 bootstraps. g, Dwell
13

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

time distributions of SARS-CoV-2 replication activity at 25Â°C (grey circles) and 37Â°C (black
circles) extracted from (b), and their respective fit to the pause-stochastic model (corresponding
solid lines). h, Nucleotide addition rate (green), Pause 1 (dark blue) and Pause 2 (cyan) exit
rates at either 25Â°C or 37Â°C (solid and hatched bars, respectively) extracted from (g). The error
bars in (c) and (g) are 36% confidence interval extracted from 1000 bootstraps. The error bars
in (h) are one standard deviation extracted from 100 bootstraps (Materials and Methods).

14

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Fig. 2. Remdesivir-TP (RDV-TP) is efficiently incorporated and dramatically increases
the average replication time. a, SARS-CoV-2 replication traces for 500 ÂµM NTPs and 500
ÂµM 3â€™-dATP; and f, for 500 ÂµM NTPs and 100 ÂµM RDV-TP. b, g, e, SARS-CoV-2 replication
product length for the 1043 nt long template using the indicated concentration of ATP, 500 ÂµM
of other NTPs, as a function of the stoichiometry of either [3â€™-dATP]/[ATP] or [RDVTP]/[ATP]. The mean values are indicated above the violin plots, and represented by horizontal
black thick lines flanked by one standard deviation error bars extracted from 1000 bootstraps.
c, h, Replication time for the reaction conditions described in (b, g). The medians are indicated
above the violin plots, and represented by horizontal black thick lines flanked by one standard
15

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

deviation error bars extracted from 1000 bootstraps. i, Dwell time distributions of SARS-CoV2 replication activity for 500 ÂµM NTPs in the absence (gray) or presence of 100 ÂµM RDV-TP
(pink). The corresponding solid lines are the fit of the pause-stochastic model. j, Nucleotide
addition rate (green), Pause 1 (dark blue) and Pause 2 (cyan) exit rates for [NTPs] = 500 ÂµM
and several [RDV-TP]. k, Probabilities to enter Pause 1 (dark blue), Pause 2 (cyan) and the
power law (red) distributed states for the conditions described in (j). In (b, e), the solid lines are
the fits of the terminator effective incorporation rate (Materials and Methods). In (a, d, g), the
insets are zoom-in of the replication traces captured in the black square. Error bars in (i) are the
36% CI from extracted from 1000 bootstraps. Error bars in (j, k) are one standard deviation
extracted from 100 bootstrap procedures (Materials and Methods).

16

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Fig. 3. T-1106-TP incorporation induces intermediate duration pauses in SARS-CoV-2
replication kinetics. a, SARS-CoV-2 replication traces in the presence of 500 ÂµM NTPs, in
the presence of 500 ÂµM T-1106-TP. The inset is a zoom-in of the replication traces captured in
the black square. b, SARS-CoV-2 replication time for the 1043 nt long template using 500 ÂµM
of all NTPs, and the indicated concentration of T-1106-TP. The median values are indicated
above the violin plots, and represented by horizontal black thick lines flanked by one standard
deviation error bars extracted from 1000 bootstraps. c, Replication product length using 500
ÂµM NTPs and the indicated concentration of T-1106-TP. The mean values are indicated above
the violin plots, and represented by horizontal black thick lines flanked by one standard
deviation error bars extracted from 1000 bootstraps. d, Dwell time distributions of SARS-CoV2 replication activity for 500 ÂµM NTP either without (gray) or with 500 ÂµM (red) T-1106-TP.
The corresponding solid lines are the fit to the pause-stochastic model. e, Nucleotide addition
rate (green), Pause 1 (dark blue) and Pause 2 (cyan) exit rates for [NTPs] = 500 ÂµM and several
T-1106-TP concentrations. f, Probabilities to enter Pause 1 (dark blue), Pause 2 (cyan) and the
power law (red) distributed states for the conditions described in (e). The error bars denote the
36% CI from 1000 bootstraps in (d). Error bars in (e, f) are one standard deviation extracted
from 100 bootstrap procedures (Materials and Methods).

17

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Fig. 4. ddhCTP is a potent inhibiteur of SARS-CoV-2 replication, Sofosbuvir-TP isnâ€™t. a,
b, SARS-CoV-2 replication traces for 500 ÂµM NTPs and 500 ÂµM of either Sofosbuvir-TP or
ddhCTP. c, d, SARS-CoV-2 replication product length using the indicated concentration of
either UTP or CTP, 500 ÂµM of other NTPs, as a function of the stoichiometry of either (b)
[Sofosbuvir-TP]/[UTP] or (c) [ddhCTP]/[CTP]. The mean values are indicated above the violin
plots, and represented by horizontal black thick lines flanked by one standard deviation error
bars extracted from 1000 bootstraps. e, f, SARS-CoV-2 replication traces in the presence 50
ÂµM of either (e) UTP or (f) CTP, 500 ÂµM of all other NTPs and 500 ÂµM of either (e) SofosbuvirTP or (f) ddhCTP. g, h, SARS-CoV-2 replication product length using 50 ÂµM either UTP or
CTP, 500 ÂµM of other NTPs, as a function of the stoichiometry of either (g) [SofosbuvirTP]/[UTP] or (h) [ddhCTP]/[CTP]. The mean values are indicated above the violin plots, and
represented by horizontal black thick lines flanked by one standard deviation error bars
extracted from 1000 bootstraps. In (f, d, h), the solid lines are the fits of the terminator effective
incorporation rate (Materials and Methods). In (a, b, e, f), the insets are a zoom-in of the
replication traces captured in the black square.

18

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

Materials and methods
High throughput magnetic tweezers apparatus
The high throughput magnetic tweezers used in this study have been described in detail
elsewhere 34. Shortly, a pair of vertically aligned permanent magnets (5 mm cubes,
SuperMagnete, Switzerland) separated by a 1 mm gap are positioned above a flow cell (see
paragraph below) that is mounted on a custom-built inverted microscope. The vertical position
and rotation of the magnets are controlled by two linear motors, M-126-PD1 and C-150 (Physik
Instrumente PI, GmbH & Co. KG, Karlsruhe, Germany), respectively. The field of view is
illuminated through the magnets gap by a collimated LED-light source, and is imaged onto a
large chip CMOS camera (Dalsa Falcon2 FA-80-12M1H, Stemmer Imaging, Germany) using
a 50Ã— oil immersion objective (CFI Plan Achro 50 XH, NA 0.9, Nikon, Germany) and an
achromatic doublet tube lens of 200 mm focal length and 50 mm diameter (Qioptic, Germany).
To control the temperature, we used a system described in details in Ref. 22. Shortly, a flexible
resistive foil heater with an integrated 10MÎ© thermistor (HT10K, Thorlabs) is wrapped around
the microscope objective and further insulated by several layers of kapton tape (KAP22-075,
Thorlabs). The heating foil is connected to a PID temperature controller (TC200 PID controller,
Thorlabs) to adjust the temperature within âˆ¼0.1Â°.

Recombinant Protein Expression of RdRp (nsp12) and cofactors (nsp7 and nsp8) from SARSCoV-2
This protocol was described in Ref. 19. SARS-CoV-2 nsp12: The SARS-CoV-2 nsp12 gene was
codon optimized and cloned into pFastBac with C-terminal additions of a TEV site and strep
tag (Genscript). The pFastBac plasmid and DH10Bac E. coli (Life Technologies) were used to
create recombinant bacmids. The bacmid was transfected into Sf9 cells (Expression Systems)
with Cellfectin II (Life Technologies) to generate recombinant baculovirus. The baculovirus
was amplified through two passages in Sf9 cells, and then used to infect 1 L of Sf21 cells
(Expression Systems) and incubated for 48 hrs at 27Â°C. Cells were harvested by centrifugation,
resuspended in wash buffer (25 mM HEPES pH 7.4, 300 mM NaCl, 1 mM MgCl2, 5 mM DTT)
with 143 Î¼l of BioLock per liter of culture. Cells were lysed via microfluidization
(Microfluidics). Lysates were cleared by centrifugation and filtration. The protein was purified
using Strep Tactin superflow agarose (IBA). Strep Tactin eluted protein was further purified by
size exclusion chromatography using a Superdex 200 Increase 10/300 column (GE Life
Sciences) in 25 mM HEPES, 300 mM NaCl, 100 Î¼M MgCl2, 2 mM TCEP, at pH 7.4. Pure
protein was concentrated by ultrafiltration prior to flash freezing in liquid nitrogen. SARS-CoV2 nsp7 and nsp8: The SARS-CoV-2 nsp7 and nsp8 genes were codon optimized and cloned
into pET46 (Novagen) with an N-terminal 6x histidine tag, an enterokinase site, and a TEV
protease site. Rosetta2 pLys E. coli cells (Novagen) were used for bacterial expression. After
induction with isopropyl Î²-D-1-thiogalactopyranoside (IPTG), cultures were grown at 16Â°C for
16 hrs. Cells were harvested by centrifugation and pellets were resuspended in wash buffer (10
mM Tris pH 8.0, 300 mM NaCl, 30 mM imidazole, 2 mM DTT). Cells were lysed via
microfluidization and lysates were cleared by centrifugation and filtration. Proteins were
purified using Ni-NTA agarose beads and eluted with wash buffer containing 300 mM
imidazole. Eluted proteins were further purified by size exclusion chromatography using a
Superdex 200 Increase 10/300 column (GE Life Sciences). Purified proteins were concentrated
by ultrafiltration prior to flash freezing with liquid nitrogen.
Recombinant Protein Expression of RdRp (nsp12) and cofactors (nsp7 and nsp8) from SARSCoV-1
This protocol was described in Ref. 12. All SARS-CoV proteins used in this study were
expressed in Escherichia coli (E. coli), under the control of T5 promoters. Cofactors nsp7L8
and nsp8 alone were expressed from pQE30 vectors with C-terminal and N-terminal hexa19

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

histidine tags respectively. TEV cleavage site sequences were included for His-tag removal
following expression. The nsp7L8 fusion protein was generated by inserting a GSGSGS linker
between nsp7- and nsp8-coding sequences. Cofactors were expressed in NEB Express C2523
(New England Biolabs) cells carrying the pRare2LacI (Novagen) plasmid in the presence of
Ampicillin (100 ÂµM/mL) and Chloramphenicol (17 Âµg/mL). Protein expression was induced
with 100 ÂµM IPTG once the OD600 = 0.5â€“0.6, and expressed overnight at 17Â°C. Protein was
purified first through affinity chromatography with HisPur Cobalt resin (Thermo Scientific),
with a lysis buffer containing 50 mM Tris-HCl pH 8, 300 mM NaCl, 10 mM Imidazole,
supplemented with 20 mM MgSO4, 0.25 mg/mL Lysozyme, 10 Âµg/mL DNase, 1 mM PMSF,
with lysis buffer supplemented with 250 mM imidazole. Eluted protein was concentrated and
dialyzed overnight in the presence of histidine labeled TEV protease (1:10 w/w ratio to
TEV:protein) for removal of the protein tag. Cleaved protein was purified through a second
cobalt column and protein was purified through size exclusion chromatography (GE, Superdex
S200) in gel filtration buffer (25 mM HEPES pH 8, 150 mM NaCl, 5mM MgCl2, 5 mM TCEP).
Concentrated aliquots of protein were flash-frozen in liquid nitrogen and stored at -80 Â°C. A
synthetic, codon-optimized SARS-CoV nsp12 gene (DNA 2.0) bearing C-terminal 8His-tag
preceded by a TEV protease cleavage site was expressed from a pJ404 vector (DNA 2.0) in E.
coli strain BL21/pG-Tf2 (Takara). Cells were grown at 37Â°C in the presence of Ampicillin and
Chloramphenicol until OD600 reached 2. Cultures were induced with 250 ÂµM IPTG and protein
expressed at 17Â°C overnight. Purification was performed as above in lysis buffer supplemented
with 1% CHAPS. Two additional wash steps were performed prior to elution, with buffer
supplemented with 20 mM imidazole and 50 mM arginine for the first and second washes
respectively. Polymerase was eluted using lysis buffer with 500 mM imidazole and
concentrated protein was purified through gel filtration chromatography (GE, Superdex S200)
in the same buffer as for nsp7L8. Collected fractions were concentrated and supplemented with
50% glycerol final concentration and stored at -20 Â°C.
Construct fabrication.
The fabrication of the RNA hairpin has been described in detail in Ref. 35. The RNA hairpin is
made of a 499 bp double-stranded RNA stem terminated by a 20 nt loop that is assembled from
three ssRNA annealed together (Extended data Fig. 1a), and two handles, one of 856 bp at the
5â€™ end and one 822 bp at the 3â€™ end. The handles include either an 343 nt digoxygenin-labeled
ssRNA or an 443 nt biotin-labeled ssRNA (Extended data Fig. 1a). Upon applied force above
~21 pN, the hairpin opens and frees a 1043 nt ssRNA template for SARS-CoV-2 replication
(Extended data Fig. 1b). To obtain the different parts of the RNA construct, template DNA
fragments were amplified via PCR, purified (Monarch PCR and DNA cleanup kit) and in vitro
transcribed (NEB HiScribeâ„¢ T7 High Yield RNA Synthesis Kit). Transcripts were then treated
with Antarctic Phosphatase and T4 Polynucleotide Kinase. RNAs were purified using the RNA
Clean & Concentrator-25 kit (Zymo Research). Individual RNA fragments were annealed and
ligated with T4 RNA ligase 2 (NEB) to assemble the RNA hairpin.
DNA sequence enoding the RNA used as template by SARS-CoV-2 (highlighted in yellow and
in grey are the loop and the ssRNA template preceding the hairpin stem where the replicase
loads, respectively)
GTTCTACATAGCGTGCAGACGTGAATTTAATCTCGCTGACGTGTAGACACAGTGC
GTCTGCTGTCGGGTCCCTCTGGTGACTGGGTAGTTGGACTTGCCCTTGGAAGACA
TAGCAAGACCCTGCCTCTCTATTGATGTCACGGCGAATGTCGGGGAGACAGCAGC
GGCTGCAGACATCAGATCGGAGTAATACTCTCCGTAACTGGCCTTCTCTGAATTC
CGACGTTGTTAAGATGGCAGAGCCCGGTAATCGCTACTTGACCAGATAAGCTTTC
CGTGGATGGTTTAGAGGAATCACATCCAAGACTGGCTAAGCACGAAGCAACTCTT
GAGTGTAAAATTGTTGTCTCCTGTATTCGGGATGCGGGTACTAGATGACTGCAGG
20

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

GACTCCGACGTTAAGTACATTACCCCGTCATAGGCGCCGTTCAGGATCACGTTAC
CGCCATAAGATGGGAGCATGACTTCTTCTCCGCTGCGCCCACGGATCCAGTAGTG
ATTAACATTCGACAGCATGCGCACTAATCACTACTGGATCCGTGGGCGCAGCGGA
GAAGAAGTCATGCTCCCATCTTATGGCGGTAACGTGATCCTGAACGGCGCCTATG
ACGGGGTAATGTACTTAACGTCGGAGTCCCTGCAGTCATCTAGTACCCGCATCCC
GAATACAGGAGACAACAATTTTACACTCAAGAGTTGCTTCGTGCTTAGCCAGTCT
TGGATGTGATTCCTCTAAACCATCCACGGAAAGCTTATCTGGTCAAGTAGCGATT
ACCGGGCTCTGCCATCTTAACAACGTCGGAATTCAGAGAAGGCCAGTTACGGAG
AGTATTACTCCGATCTGATGTCTGCAGCCGCTGCTGTCTCCCCGACATTCGCCGTG
ACATCAATAGAGAGGCAGGGTCTTGCTATGTCTTCCAAGGGCAAGTCCAACTACC
CAGTCACCAGAGGGACCCGACAGCAGACGCACTGTGTCTACACGTCAGCGAGAT
TAAATTCACGTCTGCACGCTATGTAGAACCCTCAGCCAACTCGGTCGCGTCGGA
The resulting RNA template contains 250 U (24%), 253 A (24%), 273 C (26%) and 267 G
(26%).
Flow cell assembly
The fabrication procedure for flow cells has been described in details in Ref. 34. To summarize,
we sandwiched a double layer of Parafilm by two #1 coverslips, the top one having one hole at
each end serving as inlet and outlet, the bottom one being coated with a 0.01% m/V
nitrocellulose in amyl acetate solution. The flow cell is mounted into a custom-built holder and
rinsed with ~1 ml of 1x phosphate buffered saline (PBS). 3 Âµm diameter polystyrene reference
beads are attached to the bottom coverslip surface by incubating 100 Âµl of a 1:1000 dilution in
PBS of (LB30, Sigma Aldrich, stock conc.: 1.828*1011 particles per milliliter) for ~3 minutes.
The tethering of the magnetic beads by the RNA hairpin construct relies on a digoxygenin/antidigoxygenin and biotin-streptavidin attachment at the coverslip surface and the magnetic bead,
respectively. Therefore, following a thorough rinsing of the flow cell with PBS, 50 Âµl of antidigoxigenin (50 Âµg/ml in PBS) is incubated for 30 minutes. The flow cell was flushed with 1
ml of 10 mM Tris, 1 mM EDTA pH 8.0, 750 mM NaCl, 2 mM sodium azide buffer to remove
excess of anti-digoxigenin followed by rinsing with another 0.5 ml of 1x TE buffer (10 mM
Tris, 1 mM EDTA pH 8.0 supplemented with 150 mM NaCl, 2 mM sodium azide). The surface
is then passivated by incubating bovine serum albumin (BSA, New England Biolabs, 10 mg/ml
in PBS and 50% glycerol) for 30 minutes, and rinsed with 1x TE buffer.
Single molecule RdRp replication activity experiments
20 Âµl of streptavidin coated Dynal Dynabeads M-270 streptavidin coated magnetic beads
(ThermoFisher) was mixed with ~0.1 ng of RNA hairpin (total volume 40 Âµl) and incubated
for ~5 minutes before rinsing with ~2 ml of 1x TE buffer to remove any unbound RNA and the
magnetic beads in excess. RNA tethers were sorted for functional hairpins by looking for the
characteristic jump in extension length due to the sudden opening of the hairpin during a force
ramp experiment 35 (Extended data Fig. 1b). The flow cell was subsequently rinsed with 0.5
ml reaction buffer (50 mM HEPES pH 7.9, 2 mM DTT, 2 ÂµM EDTA, 5 mM MgCl2). After
starting the data acquisition at a force that would keep the hairpin open, 100 Âµl of reaction
buffer containing either 0.6 ÂµM of nsp12, 1.8 ÂµM of nsp7 and nsp8 for SARS-CoV-2
experiments or 0.1 ÂµM of nsp12, 1 ÂµM of nsp7 and nsp8 for SARS-CoV-1 experiments, the
indicated concentration of NTPs and of nucleotide analogues (if required) were flushed in the
flow cell to start the reaction. Sofosbuvir-TP and T-1106-TP were purchased from Jena
Bioscience (Jena, Germany) and 3â€™-dATP was purchased from TriLink Biotechnologies (San
Diego, CA, USA). The experiments were conducted at a constant force of 35 pN for a duration
of 20 to 40 minutes. The camera frame rate was fixed at either 58 Hz or 200 Hz, for reaction
temperature set at either 25Â°C or 37Â°C, respectively. A custom written Labview routine 36
21

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

controlled the data acquisition and the (x-, y-, z-) positions analysis/tracking of both the
magnetic and reference beads in real-time. Mechanical drift correction was performed by
subtracting the reference bead position to the magnetic beads positions.
Data processing
The replication activity of SARS-CoV-2 core replicase converts the tether from ssRNA to
dsRNA, which concomitantly decreases the end-to-end extension of the tether. The change in
extension measured in micron was subsequently converted into replicated nucleotides ğ‘ğ‘ğ‘…ğ‘… using
the following equation:
ğ‘ğ‘ğ‘…ğ‘… (ğ¹ğ¹) = ğ‘ğ‘ âˆ™

ğ¿ğ¿ğ‘ ğ‘ ğ‘ ğ‘  (ğ¹ğ¹) âˆ’ ğ¿ğ¿ğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘š (ğ¹ğ¹)
ğ¿ğ¿ğ‘ ğ‘ ğ‘ ğ‘  (ğ¹ğ¹) âˆ’ ğ¿ğ¿ğ‘‘ğ‘‘ğ‘‘ğ‘‘ (ğ¹ğ¹)

Where, ğ¿ğ¿ğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘šğ‘š (ğ¹ğ¹), ğ¿ğ¿ğ‘ ğ‘ ğ‘ ğ‘  (ğ¹ğ¹) and ğ¿ğ¿ğ‘‘ğ‘‘ğ‘‘ğ‘‘ (ğ¹ğ¹) are the measured extension during the experiment, the
extension of a ssRNA and of a dsRNA construct, respectively, experiencing a force ğ¹ğ¹, and ğ‘ğ‘
the number of nucleotides of the ssRNA template 21. The traces were then filtered using a
Kaiser-Bessel low-pass filter with a cut-off frequency at 2 Hz. As previously described in Ref.
21
, a dwell time analysis was performed by scanning the filtered traces with non-overlapping
windows of 10 nt to measure the time (coined throughout the manuscript dwell time) for SARSCoV-2 replicase to incorporate ten successive nucleotides. The dwell times of all the traces for
a given experimental condition were assembled and further analyzed using a maximum
likelihood estimation (MLE) fitting routine to extract the parameters from the stochasticpausing model (see below).
SARS-CoV-2 replication product length analysis
To extract the product length of the replication complex, only the traces where the beginning
and the end could clearly be distinguished and for which the tether did not rupture for ten
minutes following the last observed replication activity were considered. We represented the
mean product length, as well as one standard deviation of the mean from 1000 bootstraps as
error bars.
Stochastic-pausing model
The model is described in detail in 20-22. There are many kinetic models that are consistent with
the empirical dwell-time distributions we observe, and we here work under the assumption that
the probability of pausing is low enough that there is only one rate-limiting pause in each dwelltime window. This assumption washes out most details of the kinetic scheme that connects
pauses and nucleotide addition, but allows us to determine the general form of the dwell-time
distribution without specifying how the pauses are connected to the nucleotide addition
pathway
1
(Eq. 1)
pdw (t) âˆ pna Î“ ï¿½t; Ndw ,
ï¿½
k na
Nsp

+ Q(t) ï¿½ï¿½ pn k n eâˆ’kn t +
n=1

abt
ï¿½.
2(1 + t/1s)3/2

In the above expression, the gamma function in the first term contributes the portion ğ‘ğ‘ğ‘›ğ‘›ğ‘›ğ‘› of
dwell-times that originate in the RdRp crossing the dwell-time window of size ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ base pairs
without pausing; the second term is a sum of contributions originating in pause-dominated
transitions, each contributing a fraction ğ‘ğ‘ğ‘›ğ‘› of dwell-times; the third term captures the
asymptotic power-law decay (amplitude ğ‘ğ‘bt ) of the probability of dwell-times dominated by a
backtrack. The backtracked asymptotic term needs to be regularized for times shorter than the
22

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

diffusive backtrack step. We have introduced a regularization at 1 s, but the precise timescale
does not matter, as long as it is set within the region where the exponential pauses dominate
over the backtrack. From left to right, each term of Equation 1 is dominating the distribution
for successively longer dwell-times.
A cut-off factor ğ‘„ğ‘„(ğ‘¡ğ‘¡) for short times is introduced to account for the fact that the dwell-time
window includes ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ nucleotide-addition steps,
(ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘›ğ‘›ğ‘›ğ‘› â„ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ )ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ âˆ’1
ğ‘„ğ‘„(ğ‘¡ğ‘¡) =
.
1 + (ğ‘¡ğ‘¡ğ‘¡ğ‘¡ğ‘›ğ‘›ğ‘›ğ‘› â„ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ )ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ âˆ’1
The fit results dependence on these cut-offs is negligible as long as they are introduced in
regions where the corresponding term is sub-dominant. Here the cut is placed under the center
of the elongation peak, guaranteeing that it is placed where pausing is sub-dominant.
Maximum likelihood estimation. The normalized version of Equation 1 is the dwell-time
distribution fit to the experimentally collected dwell-times {ğ‘¡ğ‘¡ğ‘–ğ‘– }ğ‘–ğ‘– by minimizing the likelihood
function 37
ğ¿ğ¿ = âˆ’ âˆ‘ğ‘–ğ‘– ln ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ (ğ‘¡ğ‘¡ğ‘–ğ‘– ) (Eq.
2)
with respect to rates and probabilistic weights.

Dominating in a dwell-time window vs. dominating in one step. The fractions ğ‘ğ‘ğ‘›ğ‘› represent the
probability that a particular rate ğ‘˜ğ‘˜ğ‘›ğ‘› dominates the dwell-time. We want to relate this to the
probability ğ‘ƒğ‘ƒğ‘›ğ‘› that a specific exit rate dominates within a one-nt transcription window.
Assuming we have labelled the pauses so that ğ‘˜ğ‘˜ğ‘›ğ‘›âˆ’1 > ğ‘˜ğ‘˜ğ‘›ğ‘› , we can relate the probability of
having rate ğ‘›ğ‘› dominating in ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘ steps to the probability of having it dominate in one step
through
ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘
ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘
ğ‘›ğ‘›
ğ‘›ğ‘›âˆ’1
(Eq. 3)
ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘
ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘
ğ‘ğ‘ğ‘›ğ‘› = ï¿½ ï¿½ ğ‘ƒğ‘ƒğ‘šğ‘š ï¿½
âˆ’ ï¿½ ï¿½ ğ‘ƒğ‘ƒğ‘šğ‘š ï¿½
,
ğ‘ğ‘0 = ğ‘ğ‘ğ‘›ğ‘›ğ‘›ğ‘› = ğ‘ƒğ‘ƒğ‘›ğ‘›ğ‘›ğ‘› = ğ‘ƒğ‘ƒ0
ğ‘šğ‘š=0

ğ‘šğ‘š=0

The first term in Equation 3 represents the probability of having no pauses longer than the ğ‘›ğ‘›ğ‘¡ğ‘¡â„
pause in the dwell-time window, and the second term represents the probability of having no
pauses longer than the (ğ‘›ğ‘› âˆ’ 1)ğ‘¡ğ‘¡â„ pause. The difference between the two terms is the probability
that the ğ‘›ğ‘›ğ‘¡ğ‘¡â„ pause will dominate. This can be inverted to yield a relation between the singlestep probabilities (ğ‘ƒğ‘ƒğ‘›ğ‘› ) and the dwell-time window probabilities (ğ‘ğ‘ğ‘›ğ‘› )
ğ‘›ğ‘›

1/ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘

ğ‘ƒğ‘ƒğ‘›ğ‘› = ï¿½ ï¿½ ğ‘ğ‘ğ‘šğ‘š ï¿½
ğ‘šğ‘š=0

ğ‘›ğ‘›âˆ’1

1/ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘

âˆ’ ï¿½ ï¿½ ğ‘ğ‘ğ‘šğ‘š ï¿½
ğ‘šğ‘š=0

,

1/ğ‘ğ‘ğ‘‘ğ‘‘ğ‘‘ğ‘‘

ğ‘ƒğ‘ƒ0 = ğ‘ğ‘0

This relationship has been used throughout the manuscript to relate our fits over a dwell-time
window to the single-step probabilities.
Maximum likelihood estimation (MLE) fitting routine
The above stochastic-pausing model was fit to the dwell time distributions using a custom
Python 3.7 routine. Shortly, we implemented a combination of simulated annealing and bound
constrained minimization to find the parameters that minimize Equation 2. We calculated the
statistical error on the parameters by applying the MLE fitting procedure on 100 bootstraps of
the original data set 38, and reported the standard deviation for each fitting parameters.
Competition between obligatory terminator nucleotide analogues and their natural nucleotide
homologues
Starting with an empty active site (E), we assume that there is direct binding competition
between the natural nucleotide (N) and the nucleotide analogue terminator (T, simply coined
terminator) that result in either the former bound (Nb) or the latter bound (Tb) to the active site.
23

bioRxiv preprint doi: https://doi.org/10.1101/2020.08.06.240325; this version posted August 6, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is
made available under aCC-BY-NC 4.0 International license.

From these states there can be any number of intermediate states before the base is either added
Tâ„N
Tâ„N
to the chain with probability ğ‘ƒğ‘ƒcat
, or unbinds from the pocket with probability 1âˆ’ğ‘ƒğ‘ƒcat
(see
figure below).
From the empty active site state (E), either a terminator (T) or a natural
nucleotide (N) can bind though direct competition with the first order binding
T
N
[T] and ğ¾ğ¾on
[N] (solid arrows represent rates) respectively. From the
rates ğ¾ğ¾on
bound states (Tb/Nb) there can be many sub steps before either incorporating
Tâ„N
, or ejecting it from the active site with
the base with probability ğ‘ƒğ‘ƒcat
Tâ„N
(dashed arrows represent probabilities).
probability and 1 âˆ’ ğ‘ƒğ‘ƒcat

The effective incorporation rate is the attempt rate times the probability of success,
T/N
T/N T/N
ğ‘˜ğ‘˜inc = [Tâ„N]ğ¾ğ¾on ğ‘ƒğ‘ƒcat
and the relative probability that next incorporated base is a terminator or natural nucleotide is
given by the relative effective addition rates
T
T
T
ğ‘ğ‘T ğ‘˜ğ‘˜inc
[T] ğ¾ğ¾on
ğ‘ƒğ‘ƒcat
=
=
,
ğ‘ğ‘T + ğ‘ğ‘N = 1.
N
N
N
ğ‘ğ‘N ğ‘˜ğ‘˜inc
[N] ğ¾ğ¾on
ğ‘ƒğ‘ƒcat
This can be rewritten as
N N
ğ›¾ğ›¾
ğ‘¥ğ‘¥
[T]
ğ¾ğ¾on
ğ‘ƒğ‘ƒcat
ğ‘ğ‘N =
,
ğ‘ğ‘T =
,
ğ‘¥ğ‘¥ =
,
ğ›¾ğ›¾ = T T
ğ›¾ğ›¾ + ğ‘¥ğ‘¥
ğ›¾ğ›¾ + ğ‘¥ğ‘¥
[N]
ğ¾ğ¾on ğ‘ƒğ‘ƒcat
In the above ğ‘¥ğ‘¥ is the relative stoichiometry between T and N, while ğ›¾ğ›¾ is the relative effective
incorporation rates of N and T at equimolar conditions.
On an infinite construct, polymerization will proceed until the first T is incorporated, after
which it terminates. At termination, the product has incorporated ğ‘›ğ‘› âˆ’ 1 Ns, and finally one T,
with probability
ğ‘ƒğ‘ƒ(ğ‘›ğ‘›) = (ğ‘ğ‘N )ğ‘›ğ‘›âˆ’1 ğ‘ğ‘T = (1 âˆ’ ğ‘ğ‘T )ğ‘›ğ‘›âˆ’1 ğ‘ğ‘T .
The average number of Ns and Ts incorporated on an infinite construct is therefore
âˆ

âˆ

ğ‘›ğ‘› = ï¿½ ğ‘›ğ‘›(ğ‘ğ‘N )ğ‘›ğ‘›âˆ’1 ğ‘ğ‘T = 1/ğ‘ğ‘T .
ğ‘›ğ‘›=1

If the construct only allows for the addition of ğ‘ğ‘ Ns and Ts, the average number of Ns and Ts
in the product will instead be
ğ‘ğ‘

ğ‘ğ‘

ğ‘›ğ‘› = ï¿½ ğ‘›ğ‘›A
ğ‘›ğ‘›=1

(ğ‘ğ‘N )ğ‘›ğ‘›âˆ’1 T

âˆ

ğ‘ğ‘ + ï¿½ ğ‘ğ‘(ğ‘ğ‘N )ğ‘›ğ‘›âˆ’1 ğ‘ğ‘T =
ğ‘›ğ‘›=ğ‘ğ‘+1

1 âˆ’ (ğ‘ğ‘N )ğ‘ğ‘
= ğ‘›ğ‘›âˆ (1 âˆ’ (ğ‘ğ‘N )ğ‘ğ‘ ).
ğ‘ğ‘T

For a genome of length ğ¿ğ¿, with the relative abundance ğ‘ğ‘ of templating bases for N and T, we
thus expect there to be at most ğ‘ğ‘ = ğ‘ğ‘ğ‘ğ‘ Ns and Ts incorporated at termination. At termination
the product then has the average length
ğ‘›ğ‘›ğ‘ğ‘ğ‘ğ‘ 1 âˆ’ (ğ‘ğ‘N )ğ‘ğ‘ğ‘ğ‘
1
ğ¿ğ¿
=
= ğ‘™ğ‘™ âˆ (1 âˆ’ (ğ‘ğ‘N )ğ‘ğ‘ğ‘ğ‘ ),
ğ‘™ğ‘™ âˆ =
ğ‘™ğ‘™ =
T
ğ‘ğ‘
ğ‘ğ‘ ğ‘ğ‘
ğ‘ğ‘ ğ‘ğ‘T
Data fitting
Though the constructs are 1043 nucleotides long, this length is not always reached even when
there are no terminators in the buffer. The average product length is about 10% shorter than the
full construct length. To account for this reduction in maximal average product length, we
simply fix ğ¿ğ¿ to be the mean product length reached without terminator in the buffer, and fit out
ğ›¾ğ›¾ from a least square fit, weighted with the inverse experimental variance.
24

